NCT03430011: Phase 1/2 - Autologous BCMA-specific CAR-T cells JCARH125 in RRMM (EVOLVE)
NCT03601078: Phase 2 -Efficacy and Safety of bb2121 in relapsed MM & in high risk Myeloma (KarMMa-2)
NCT03651128: Phase 3 - Study of bb2121 Vs Standard Regimens Refractory Myeloma (RRMM) (KarMMa-3)
NCT03672318: Phase 1: Study of ATLCAR.CD138 Cells for Relapsed/Refractory Multiple Myeloma
NCT03435796: Phase 2/3: Long-Term Follow-up for Participants Treated With Gene-Modified T Cells
NCT03752541: Allogeneic T-cells with Anti-BCMA CAR - BCMA-UCART in RRMM - Chinese study
NCT03758417: Phase 2 - LCAR-B38M CAR-T Cells Against BCMA in Chinese relapsed Myeloma (CARTIFAN - 1)
NCT03716856: Phase 1 - CAR-BCMA T in Patients With Refractory or Relapsed Multiple - Chinese study
NCT03502577: Phase 1 - BCMA-Specific CAR T-Cells Combined With Gamma Secretase Inhibitor (JSMD194)
NCT03448978: Phase 1/2 - Descartes-08 - anti-BCMA-CAR-mRNA-trans. auto CD8+ T cells in Myeloma
NCT03464916: Phase 1: Study to Evaluate the Safety and Efficacy of Anti-CD38 CAR-T in RRMM
NCT03274219 : Phase 1 - bb21217 an Anti-BCMA CAR T Cell Drug Product, in RRMM - CRB-402
NCT03090659: Phase 1/2 - A Chinese study of LCAR-B38M CAR-T cells in RRMM -Myeloma (LEGEND-2)
NCT03318861: Phase 1: Study to Evaluate the Safety and Efficacy of KITE-585 in RRMM Multiple Myeloma
NCT03338972: Phase 1 - Autologous Anti-BCMA-CAR-expressing CD4+/CD8+ T-lymphocytes FCARH143 in RRMM
NCT03288493: Phase 1/2 - P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Myeloma
NCT03070327: Phase 1 - BCMA Targeted CAR T Cells With or Without Lenalidomide for Multiple Myeloma
NCT03380039: Phase 1 - Clinical Study of CAR-BCMA T Cells in Patients With RRMM
NCT03361748 : KarMMa - Phase 2 - To Determine the Efficacy and Safety of bb2121 in refractory MM